ATA422281A - Verfahren zur herstellung des hydrochloridsalzes des h2-antagonisten n-(2-(((5-(dimethylamino)methyl)-2-furanyl)-methyl)-thio)-|thyl-n1-methy -2-nitro-1,1-aethendiamin - Google Patents
Verfahren zur herstellung des hydrochloridsalzes des h2-antagonisten n-(2-(((5-(dimethylamino)methyl)-2-furanyl)-methyl)-thio)-|thyl-n1-methy -2-nitro-1,1-aethendiaminInfo
- Publication number
- ATA422281A ATA422281A AT0422281A AT422281A ATA422281A AT A422281 A ATA422281 A AT A422281A AT 0422281 A AT0422281 A AT 0422281A AT 422281 A AT422281 A AT 422281A AT A422281 A ATA422281 A AT A422281A
- Authority
- AT
- Austria
- Prior art keywords
- methyl
- aethendiamin
- thyl
- methy
- furanyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT223188A AT407956B (de) | 1980-10-01 | 1988-09-12 | Verfahren zur herstellung eines arzneimittels |
AT109189A AT402069B (de) | 1980-10-01 | 1989-05-08 | Eine neue kristallform des hydrochloridsalzes des h2-antagonisten n-(2-(((5-(dimethylamino)-methyl)-2-furanyl)-me hyl)-thio)-äthyl-n1-methyl-2-nitro- 1, 1-äthendiamin (ranitidin) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8031634 | 1980-10-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
ATA422281A true ATA422281A (de) | 1989-06-15 |
AT389696B AT389696B (de) | 1990-01-10 |
Family
ID=10516407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT0422281A AT389696B (de) | 1980-10-01 | 1981-10-01 | Verfahren zur herstellung des hydrochloridsalzes des h2-antagonisten n-(2-(((5-(dimethylamino)methyl)-2-furanyl)-methyl)-thio)-|thyl-n1-methy -2-nitro-1,1-aethendiamin |
Country Status (29)
Country | Link |
---|---|
US (2) | US4521431A (de) |
JP (1) | JPS5791983A (de) |
KR (1) | KR870001431B1 (de) |
AT (1) | AT389696B (de) |
AU (1) | AU549119B2 (de) |
BE (1) | BE890574A (de) |
CA (1) | CA1202638A (de) |
CH (1) | CH652122A5 (de) |
CZ (1) | CZ280885B6 (de) |
DE (1) | DE3139134A1 (de) |
DK (2) | DK167794B1 (de) |
ES (1) | ES8301954A1 (de) |
FR (1) | FR2491067A1 (de) |
GR (1) | GR72499B (de) |
HK (1) | HK97985A (de) |
IE (1) | IE51604B1 (de) |
IL (1) | IL63968A (de) |
IT (1) | IT1143237B (de) |
KE (1) | KE3549A (de) |
LU (1) | LU83661A1 (de) |
MY (1) | MY8500747A (de) |
NL (1) | NL8104482A (de) |
NZ (1) | NZ198522A (de) |
PH (2) | PH19489A (de) |
PT (1) | PT73744B (de) |
SE (1) | SE453500B (de) |
SK (1) | SK277922B6 (de) |
ZA (1) | ZA816809B (de) |
ZW (1) | ZW24481A1 (de) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1279328C (en) * | 1983-07-15 | 1991-01-22 | Janos Borvendeg | Process for preparing basic thioethers and the salts thereof |
GB8629781D0 (en) * | 1986-12-12 | 1987-01-21 | Glaxo Group Ltd | Pharmaceutical compositions |
SE8704436D0 (sv) * | 1987-11-13 | 1987-11-13 | Pm Konsult Handelsbolag | Anvendning av antisekretoriska substanser for nya indikationer |
IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it |
GB8904182D0 (en) * | 1989-02-23 | 1989-04-05 | Glaxo Canada | Pharmaceutical compositions |
US5169864A (en) * | 1991-11-15 | 1992-12-08 | Baxter International Inc. | Unbuffered premixed ranitidine formulation |
US5338871A (en) * | 1991-12-20 | 1994-08-16 | Torcan Chemical Ltd. | Preparation of form 1 ranitidine hydrochloride |
CN1048984C (zh) * | 1991-12-20 | 2000-02-02 | 多坎化学有限公司 | 晶形1呋喃硝胺氢氯化物的制备 |
PL184611B1 (pl) * | 1993-03-12 | 2002-11-29 | Upjohn Co | Krystaliczny ceftiofur w postaci wolnego kwasu sposób jego wytwarzania oraz kompozycja farmaceutyczna zawierająca krystaliczny ceftiofur w postaci wolnego kwasu |
DE4341310A1 (de) * | 1993-12-03 | 1995-06-08 | Hexal Pharma Gmbh | Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1 |
US5407687A (en) * | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
CA2120874E (en) * | 1994-04-08 | 2002-01-08 | Keshava Murthy | Form of form 1 ranitidine |
US5670671A (en) * | 1994-04-08 | 1997-09-23 | Brantford Chemicals Inc. | Process for the production of an improved form of form 1 ranitidine |
PT755393E (pt) | 1994-04-15 | 2002-04-29 | Upjohn Co | Novas formas cristalinas de 1-¬5-metanossulfonamidoimdolil-2-carbonil|-4-¬3-(1-metiletilamino)-2-piridinil|piperazina |
IN181699B (de) * | 1994-05-13 | 1998-09-05 | Ranbaxy Lab Ltd | |
IN181698B (de) * | 1994-05-13 | 1998-09-05 | Ranbaxy Lab Ltd | |
NZ272054A (en) * | 1994-05-13 | 1996-05-28 | Ranbaxy Lab Ltd | Process for producing form 1 ranitidine hydrochloride |
WO1995031437A1 (en) * | 1994-05-18 | 1995-11-23 | Hoechst Marrion Roussel, Inc. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof |
US20030045722A1 (en) * | 1994-05-18 | 2003-03-06 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
DE69504156T2 (de) | 1994-06-24 | 1998-12-24 | Ranbaxy Laboratories, Ltd., New Delhi | Verfahren zur Herstellung von Ranitidinhydrochlorid in der Kristallform 1 |
PL320190A1 (en) * | 1994-11-18 | 1997-09-15 | Upjohn Co | Novel, physically stable form of fuoroquinolone |
US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
US5663381A (en) * | 1995-04-21 | 1997-09-02 | Hexal Pharmaceuticals, Inc. | Process for preparing form 1 ranitidine hydrochloride |
US5686588A (en) * | 1995-08-16 | 1997-11-11 | Yoo; Seo Hong | Amine acid salt compounds and process for the production thereof |
WO1997035853A1 (en) * | 1996-03-25 | 1997-10-02 | Hoechst Marion Roussel, Inc. | Process for the preparation of form 1 ranitidine hydrochloride |
DE59801792D1 (de) * | 1997-08-08 | 2001-11-22 | Aventis Pharma Gmbh | Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid |
US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
IT1317858B1 (it) | 2000-02-29 | 2003-07-15 | Pharmexcel S R L | Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione |
GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
US20020183553A1 (en) * | 2000-10-19 | 2002-12-05 | Ben-Zion Dolitzky | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
US6569887B2 (en) * | 2001-08-24 | 2003-05-27 | Dov Pharmaceuticals Inc. | (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake |
US20060173064A1 (en) * | 2001-08-24 | 2006-08-03 | Lippa Arnold S | (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders |
US7235655B2 (en) * | 2002-03-22 | 2007-06-26 | Pharmacia & Upjohn Company | Processes to prepare eplerenone |
TW200409746A (en) * | 2002-07-26 | 2004-06-16 | Theravance Inc | Crystalline β2 adrenergic receptor agonist |
US20080081834A1 (en) | 2002-07-31 | 2008-04-03 | Lippa Arnold S | Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders |
US7166641B2 (en) * | 2002-10-02 | 2007-01-23 | Yung Shin Pharmaceutical Industrial Co., Ltd. | Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same |
RU2005117630A (ru) * | 2002-11-08 | 2006-01-20 | Дов Фармасьютикал, Инк. (Us) | Полиморфы гидрохлорида бицифадина |
TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
US7384557B2 (en) * | 2003-07-14 | 2008-06-10 | Applied Ambient Extraction Process Consultants, Llc | Method and apparatus for removing solute from a solid solute-bearing product |
TWI328006B (en) | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
US20070043100A1 (en) | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
US20060100263A1 (en) * | 2004-11-05 | 2006-05-11 | Anthony Basile | Antipyretic compositions and methods |
US20060100271A1 (en) * | 2004-11-08 | 2006-05-11 | Keith Whitehead | Stabilized aqueous ranitidine compositions |
AU2006275870B2 (en) | 2005-07-27 | 2013-01-10 | Otsuka America Pharmaceutical, Inc. | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders |
DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
US20080045725A1 (en) * | 2006-04-28 | 2008-02-21 | Murry Jerry A | Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane |
CA2756603C (en) * | 2006-10-20 | 2013-05-28 | Scinopharm Singapore Pte, Ltd. | Process for making crystalline docetaxel trihydrate |
US8138377B2 (en) | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
EP2167083B1 (de) * | 2007-06-06 | 2015-10-28 | Euthymics Bioscience, Inc. | 1- heteroaryl-3-azabicyclo[3.1.0]hexane, verfahren zu ihrer herstellung und ihre verwendung als medikamente |
US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
TW201011043A (en) * | 2008-06-20 | 2010-03-16 | Chugai Pharmaceutical Co Ltd | Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives |
DK2727912T3 (en) | 2011-06-30 | 2017-07-17 | Toray Industries | Glycine derivative crystals and their pharmaceutical use |
US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
CN106432148B (zh) * | 2015-05-26 | 2018-04-17 | 烟台市华文欣欣医药科技有限公司 | 一种治疗胃病的药物盐酸雷尼替丁化合物的制备方法 |
CN105030694A (zh) * | 2015-08-04 | 2015-11-11 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂 |
CN104971053A (zh) * | 2015-08-05 | 2015-10-14 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂 |
CN105055331A (zh) * | 2015-08-31 | 2015-11-18 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂 |
WO2021079183A1 (en) * | 2019-10-21 | 2021-04-29 | Sms Pharmaceuticals Limited | Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1565966A (en) * | 1976-08-04 | 1980-04-23 | Allen & Hanburys Ltd | Aminoalkyl furan derivatives |
US4233302A (en) * | 1977-12-23 | 1980-11-11 | Glaxo Group Limited | Amine derivatives and pharmaceutical compositions containing them |
-
1981
- 1981-09-28 IL IL63968A patent/IL63968A/xx unknown
- 1981-09-29 PT PT73744A patent/PT73744B/pt unknown
- 1981-10-01 IE IE2287/81A patent/IE51604B1/en not_active IP Right Cessation
- 1981-10-01 ZW ZW244/81A patent/ZW24481A1/xx unknown
- 1981-10-01 BE BE0/206126A patent/BE890574A/fr not_active IP Right Cessation
- 1981-10-01 CH CH6322/81A patent/CH652122A5/fr not_active IP Right Cessation
- 1981-10-01 LU LU83661A patent/LU83661A1/fr unknown
- 1981-10-01 NL NL8104482A patent/NL8104482A/nl active Search and Examination
- 1981-10-01 AT AT0422281A patent/AT389696B/de not_active IP Right Cessation
- 1981-10-01 CA CA000387135A patent/CA1202638A/en not_active Expired
- 1981-10-01 ES ES505951A patent/ES8301954A1/es not_active Expired
- 1981-10-01 PH PH26300A patent/PH19489A/en unknown
- 1981-10-01 ZA ZA816809A patent/ZA816809B/xx unknown
- 1981-10-01 JP JP56154887A patent/JPS5791983A/ja active Granted
- 1981-10-01 KR KR1019810003689A patent/KR870001431B1/ko not_active IP Right Cessation
- 1981-10-01 GR GR66187A patent/GR72499B/el unknown
- 1981-10-01 IT IT49407/81A patent/IT1143237B/it active
- 1981-10-01 DE DE19813139134 patent/DE3139134A1/de active Granted
- 1981-10-01 SE SE8105812A patent/SE453500B/sv not_active IP Right Cessation
- 1981-10-01 FR FR8118528A patent/FR2491067A1/fr active Granted
- 1981-10-01 NZ NZ198522A patent/NZ198522A/en unknown
- 1981-10-01 AU AU75955/81A patent/AU549119B2/en not_active Expired
- 1981-10-01 DK DK436281A patent/DK167794B1/da not_active IP Right Cessation
-
1982
- 1982-08-09 US US06/406,710 patent/US4521431A/en not_active Expired - Lifetime
-
1985
- 1985-03-18 US US06/712,610 patent/US4672133A/en not_active Expired - Lifetime
- 1985-07-17 KE KE3549A patent/KE3549A/xx unknown
- 1985-12-05 HK HK979/85A patent/HK97985A/xx not_active IP Right Cessation
- 1985-12-20 PH PH33229A patent/PH21761A/en unknown
- 1985-12-30 MY MY747/85A patent/MY8500747A/xx unknown
-
1991
- 1991-12-23 SK SK4035-91A patent/SK277922B6/sk unknown
- 1991-12-23 CZ CS914035A patent/CZ280885B6/cs unknown
-
1992
- 1992-03-12 DK DK033792A patent/DK167923B1/da not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATA422281A (de) | Verfahren zur herstellung des hydrochloridsalzes des h2-antagonisten n-(2-(((5-(dimethylamino)methyl)-2-furanyl)-methyl)-thio)-|thyl-n1-methy -2-nitro-1,1-aethendiamin | |
AT382373B (de) | Verfahren zur herstellung von neuen 2-(4-(4,4dialkyl-2,6-piperidin-dion-1-yl)-butyl)-1piperazinyl)-pyrimidinen | |
DE59103711D1 (de) | Verfahren zur herstellung hellfarbiger pasten von alpha-sulfofettsäurealkylester-alkalimetallsalzen. | |
AT375367B (de) | Verfahren zur herstellung von als histamin h2-rezeptor-antagonisten wirkenden nitroverbindungen | |
AT368499B (de) | Verfahren zur herstellung von neuen 5-substituierten pyranon-verbindungen | |
AT377262B (de) | Verfahren zur herstellung des neuen 2-(3-(4- | |
AT363955B (de) | Verfahren zur herstellung von n-cyano-n'-(2-((4 -methyl-5-imidazolyl)methylthio)aethyl)-n''-alkinylguanidinen | |
AT355557B (de) | Verfahren zur herstellung von neuen alpha-aryl- alpha, alpha-bis(omega- (disubstituiertes amino)alkyl)acetamiden | |
DE3875447D1 (de) | Chemisches verfahren zur herstellung von methyl 2-(3-phenoxypyrid-2-yl)-3-propenoaten. | |
AT358044B (de) | Verfahren zur herstellung von mefloquin | |
AT374475B (de) | Verfahren zur herstellung von blutdrucksenkendem 6,7-dimethoxy-4-amino-2-(4-(2-furoyl)-1piperazinyl) chinazolinhydrochlorid | |
ATA225078A (de) | Verfahren zur herstellung von 2-(2',2',2'- trihalogenaethyl)-4-halogencyclobutan-1-onen | |
AT367026B (de) | Verfahren zur herstellung von 2-(2-hydroxyaethoxy) aethyl-n-(alpha,alpha,alpha-trifluor-m-tolyl) anthranilat | |
AT383597B (de) | Verfahren zur herstellung des neuen n-(2-(((5it81081823546/8 | |
AT369365B (de) | Verfahren zum herstellen von neuen 5-(2-((2,3dihydro-1,4-benzodioxan-2-ylmethyl)-amino)-1hydroxy[thyl)-2-hydroxybenzoes[urederivaten | |
ATE6502T1 (de) | Verfahren zur herstellung von n-(1'alkoxycarbonyl[thyl)-2,6-dialkylanilinen. | |
DE2967648D1 (en) | Utilisation of 2-(n-(2,6-dichloro-phenyl)-n-allyl-amino)-imidazoline-(2) for the production of bradycardiac drugs | |
AT386200B (de) | Verfahren zur herstellung von n-(2-(((5-(dimethyl-amino)-methyl-2-furanyl)met yl)thio)-aethyl)-n' -methyl-2-nitro-1,1-aethendiamin | |
ATA109189A (de) | Eine neue kristallform des hydrochloridsalzes des h2-antagonisten n-(2-(((5-(dimethylamino)-methyl)-2-furanyl)-me hyl)-thio)-äthyl-n1-methyl-2-nitro- 1, 1-äthendiamin (ranitidin) | |
ATA260889A (de) | Verfahren zur herstellung des neuen n-(2-( (2-guanidinothiazol-4-yl)methylthio)-ethyl)- ethandiimidamids | |
ATE5136T1 (de) | Verfahren zur herstellung von n-(1'alkoxycarbonyl[thyl)-2,6-dialkylanilinen. | |
AT353771B (de) | Verfahren zur herstellung von neuen 2-(2',2'- dihalogenvinyl)-oder(2',2',2'-trihalogenaethyl)- cyclobutanonen | |
ATA179289A (de) | Verfahren zur herstellung des neuen n-(2-((2guanidinothiazol-4-yl)methyl-thio)ethyl)ethandiimidamids | |
AT374195B (de) | Verfahren zur herstellung von 2-(2-thenoylthio) -propionylglycin | |
ATA239690A (de) | Verfahren zur herstellung des 5-(4-hydroxyphenyl)-hydantoins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ELA | Expired due to lapse of time |